secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001104659-25-077200
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Q2 net loss $10.4M, cash $135.5M; denifanstat meets all acne Phase 3 endpoints
--------------------------------------------------------------------------------

- Net loss Q2 2025 $10.4M vs $8.1M; H1 loss $28.6M vs $14.7M; R&D and G&A both increased.
- Cash position $135.5M at June 30, 2025; no revenue reported (pre-revenue biotech).
- Denifanstat Phase 3 acne trial (Ascletis) met all endpoints: treatment success 33.2% vs 14.6% (p<0.0001).
- Initiated Phase 1 for TVB-3567 (acne) in U.S.; combo trial denifanstat+resmetirom PK study planned 2H 2025 with readout 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/0001104659-25-077200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-077200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer